New Insights into Alzheimer’s Disease Progression

Alzheimer’s disease features the accumulation of a toxic protein known as Tau, which harms and ultimately kills brain cells. As Tau spreads through various brain regions, the condition worsens, leading to greater memory impairment and cognitive issues.

Recent research has shed light on an unexpected element in this process. In studies using mice, scientists discovered that a brain protein called Arc, which typically facilitates neuron communication, also seems to assist in the transport of harmful Tau from sick cells to healthy ones.

This finding suggests a new approach to slowing down Alzheimer’s. Instead of trying to completely eliminate Tau, future treatments might focus on preventing its spread to healthy brain cells.

“It’s exciting that we’ve found a new potential way to halt the progression of Alzheimer’s disease,” remarks a neurobiology professor involved in the study.

Arc’s Role in Tau Transmission

To explore how Alzheimer’s spreads, researchers compared mice with and without the Arc protein. Their experiments demonstrated that Arc is crucial for transferring toxic Tau between neurons.

Under typical circumstances, Arc is vital for proper brain function, helping package itself within tiny membrane-bound sacs called extracellular vesicles (EVs) that carry important signals between neurons.

The study revealed that toxic Tau can misuse this communication system. By binding to Arc in these vesicles, Tau effectively travels from unhealthy neurons to healthy ones, perpetuating the disease.

Tau’s Impact on Healthy Cells

While all neurons contain Tau, in Alzheimer’s, it forms large, sticky clusters that disrupt the cell’s transport functions and ultimately lead to cell death. A researcher involved likened these clusters to “glue monsters.”

“They act like glue, blocking transport within the neuron,” she explains. “However, they can break apart into smaller pieces, termed Tau seeds, which can be transferred to a new neuron. Once these seeds interact with healthy Tau, they can corrupt it, restarting the harmful cycle.”

In their mouse model, the team identified EVs that carried both Arc and sticky Tau, which could infiltrate healthy cells and instigate new Tau tangles.

The scenario changed significantly when Arc was absent. Mice without the protein showed very few EVs containing Tau, making it challenging for the disease to spread to adjacent brain cells.

“When we took Arc out, the transfer of Tau was drastically reduced,” the researcher noted. “It almost disappeared.”

The Dual Nature of Arc

While the idea of inhibiting Arc might seem straightforward for treatment, the researchers found that it also plays a protective role in the disease’s early stages.

Arc helps neurons eliminate excess toxic Tau, allowing damaged cells to survive longer. In mice lacking Arc, toxic Tau remained trapped inside neurons, causing a quicker decline.

“Without Arc, Tau gets stuck and accumulates to dangerous levels,” one researcher explains. “With Arc, Tau can escape in EVs—this reduces buildup in the original neuron, but allows released Tau to infect surrounding healthy neurons.”

This suggests that the best treatment approach might not involve preventing Tau release from sick cells but instead halting the entry of those toxic EVs into healthy neurons.

Exploring New Therapeutic Avenues

The researchers discovered EVs containing both Arc and Tau in human brain tissue, indicating that this mechanism might also occur in people. However, they caution that further research is essential before any therapy can be developed.

“Most of our work is in mice, not humans,” the professor points out. “We have indications that what happens in mice could also apply to humans, but it’s uncertain. We are still far from developing a therapeutic option.”

One interesting prospect would be to intercept Tau-containing EVs soon after they exit diseased neurons but before they can affect healthy ones. While this wouldn’t reverse any existing brain damage, it could potentially hinder the disease’s advance.

“If we could target these specific EVs, it might be a valuable therapeutic strategy,” the professor suggests. “For those experiencing early-onset Alzheimer’s or dementia, stopping the spread could prevent further degradation and cognitive decline.”

The study, titled “Arc mediates intercellular tau transmission via extracellular vesicles,” appeared in a scientific journal.

This research received support from various health organizations, including the National Institutes of Health and others.